BACKGROUND: Preterm infants with respiratory distress syndrome (RDS) given inositol had reduced bronchopulmonary dysplasia (BPD), death and severe retinopathy of prematurity (ROP). We assessed the safety and pharmacokinetics of daily inositol to select a dose providing serum levels previously associated with benefit, and to learn if accumulation occurred when administered throughout the normal period of retinal vascularization. METHODS: Infants
Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants
Phelps, DL., Ward, RM., Williams, R., Nolen, T., Watterberg, KL., Oh, W., Goedecke, D., Ehrenkranz, RA., Fennell, T., Poindexter, BB., Cotten, CM., Hallman, M., Frantz, ID., Faix, RG., Zaterka-Baxter, K., Das, A., Ball, MB., Lacy, CB., Walsh, MC., ... Higgins, RD. (2016). Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatric Research, 80(2). https://doi.org/10.1038/pr.2016.97
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Community overdose surveillance
Epigenetic biomarkers for smoking cessation